Biologics

A hydrogel that adheres firmly to cartilage and meniscus

November 21, 2018, Ecole Polytechnique Federale de Lausanne EPFL researchers have developed a hydrogel – made up of nearly 90% water – that naturally adheres to soft tissue like cartilage and the meniscus. If the hydrogel carries repair cells, it could help damaged tissue to heal. Some types of body tissue, like cartilage and meniscus, have

By |2018-11-21T22:03:18+00:00November 21st, 2018|Biologics|

Clinical Launch of SurGenTec® GraftGun® System Prefilled with ViBone® a Resounding Success

November 21, 2018 BOCA RATON, Fla.--(BUSINESS WIRE)--SurGenTec announced today the successful completion of the initial clinical launch of its new GraftGun bone graft delivery system combined with ViBone Viable Bone Matrix prefilled tubes. This early evaluation of the combined products was focused in the Minimally Invasive Spine (MIS) surgery field. Earlier this year, SurGenTec and

By |2018-11-21T20:52:24+00:00November 21st, 2018|Biologics|

Innovasis Enters Partnership with Stability Biologics

SALT LAKE CITY, November 19, 2018 – Innovasis, Inc., a fully integrated research, development and manufacturing spinal device company, today announced their expansion into the biologics market by signing a private-label agreement with Stability Biologics, LLC. Stability Biologics®, headquartered in Nashville, Tennessee with a state of-the-art AATB accredited and FDA registered tissue processing and distribution

By |2018-11-21T15:25:10+00:00November 21st, 2018|Biologics|

BONESUPPORT™ – Positive Results From The CERTiFy Study Comparing Cerament®|Bone Void Filler With Autograft

Lund, Sweden, 08.00 CET, 19 November 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, today announces positive top-line data from the CERTiFy (CERAMENT® Treatment of Tibia Plateau Fracture defects) study comparing CERAMENT|BVF with autologous iliac bone graft (autograft).BONESUPPORT CEO Emil Billback said:” Successfully completing the ground-breaking CERTiFy study, to demonstrate CERAMENT BVF is non-inferior to autograft

By |2018-11-19T16:20:56+00:00November 19th, 2018|Biologics|

AlloSource Granted Patent For Proprietary Laser Cutting Enclosure

CENTENNIAL, Colo., Nov. 16, 2018 /PRNewswire/ -- AlloSource, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, received U.S. patent 10,105,793, titled Enclosure for laser cutting of human tissue. This patent encompasses AlloSource's method of producing a closed system that allows a laser beam to pass through and etch allograft tissue, while maintaining

By |2018-11-16T20:40:28+00:00November 16th, 2018|Biologics|

Integra LifeSciences Appoints Eric Schwartz, Corporate Vice President, General Counsel and Secretary

PLAINSBORO, N.J., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the appointment of Eric Schwartz as corporate vice president, general counsel and secretary. “I am pleased to welcome Eric as our new general counsel and latest member of the executive leadership team,” said Peter Arduini, president and chief executive officer, Integra LifeSciences.

By |2018-11-12T21:43:48+00:00November 12th, 2018|Biologics|

Patients With Knee Cartilage Defects Recruited For Chicago Study Using Cutting-Edge Procedure To Help Regrow Cartilage

CHICAGO, Nov. 8, 2018 /PRNewswire/ -- Active people who are struggling with knee pain or knee cartilage abnormalities may benefit from a Rush University Medical Center clinical trial using an innovative new procedure for cartilage regrowth. Drs. Adam B. Yanke and Brian Cole, orthopedic surgeons and sports medicine physicians at  Midwest Orthopaedics at Rush (MOR) are some of the only physicians nationwide conducting clinical trials

By |2018-11-08T17:28:35+00:00November 8th, 2018|Biologics|

MiMedx To Present Clinical And Scientific Studies At Desert Foot Conference

MARIETTA, Ga., Nov. 6, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that five poster abstracts reporting on the Company's EpiFix® dehydrated Human Amnion/Chorion Membrane (dHACM) allograft and EpiCord® dehydrated human umbilical cord (dHUC) allograft will be presented at the Desert Foot 15th Annual Multi-Disciplinary Limb Salvage Conference

By |2018-11-06T18:04:22+00:00November 6th, 2018|Biologics|

Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway

WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, today provided an update on the NeoCart regulatory pathway based on preliminary feedback from the Type C meeting held with the U.S. Food and

By |2018-11-01T22:04:05+00:00November 1st, 2018|Biologics, Regulatory|

Amedica Announces Corporate Name Change to SINTX Technologies, Inc.

SALT LAKE CITY, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride for biomedical applications, announced that it has changed its corporate name to SINTX Technologies, Inc. in order to better reflect its focus on silicon nitride science and technologies and robust pipeline of silicon nitride

By |2018-10-31T17:04:11+00:00October 31st, 2018|Biologics, Top Stories|